Market News & Trends
Syneos Health Launches “Lab to Life” Enterprise Partnership With Komodo Health
Syneos Health recently announced it has expanded its relationship with Komodo Health, a data-driven healthcare software company with access to the broadest array of real-world…
Scipher Applies Spectra Platform to Discover Drugs Targeting Autoimmune Patients Refractory to Existing Therapies
Scipher Medicine recently announced the launch of Scipher Therapeutics, focused on discovering new targets and drugs for patients not responding to approved therapies in the…
Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE 327 Against All Six ESKAPE Pathogens
Recce Pharmaceuticals Ltd recently announced announce RECCE 327 (R327) has demonstrated bactericidal activity against all six antibiotic resistant ESKAPE pathogens, including drug-resistant mutations (superbugs) as…
Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery & Development Programs
Cocrystal Pharma, Inc. recently announced progress in developing broad-spectrum antiviral drug candidates that target coronaviruses including SARS-CoV-2, the coronavirus that causes COVID-19. Cocrystal initiated its…
ScienceMedia & Area9 Lyceum Partner to Deliver Clinical Education for Life Sciences on Area9 Rhapsode Adaptive Learning Platform
ScienceMedia Inc. and Area9 Lyceum recently announced their partnership in life sciences education in which ScienceMedia’s SMi Source therapeutic area training library, used by leading life sciences companies…
Vetter & Rentschler Biopharma Further Strengthen Strategic Alliance
Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations (CDMOs), recently announced their strategic collaboration has taken key steps….
Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results
Daré Bioscience, Inc. recently announced that data from the DARE-BVFREE Phase 3 study of DARE-BV1, a thermosetting vaginal gel for the treatment of bacterial vaginosis, was….
InveniAI & Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration
InveniAI LLC recently announced a multi-target drug discovery collaboration with Shionogi & Co., Ltd.; the multi-year collaboration will combine InveniAI’s AI platform….
AavantiBio & Catalent Announce Partnership to Support Development & Manufacturing of Gene Therapies
AavantiBio and Catalent recently announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA)….
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate
Voyager Therapeutics, Inc. recently announced the US FDA has removed its clinical hold on the company’s Investigational New Drug (IND) application for VY-HTT01, a gene…
ENZYVANT Resubmits BLA to FDA for RVT-802 for Pediatric Congenital Athymia
Enzyvant recently announced the resubmission of the Biologics Licensing Application (BLA) to the US FDA for RVT-802, cultured human thymus tissue. RVT-802 is a one-time…
Stirling Ultracold & Catalent Announce Partnership to Establish Energy-Efficient Cold Chain Capabilities for Biologics & Emerging Modalities
Catalent and Stirling Ultracold recently announced a partnership whereby Stirling Ultracold becomes the preferred provider of ULT storage across Catalent’s multiple business units. The growth…
ImCheck Announces Initiation of US Enrollment in Phase 1/2a EVICTION Trial for ICT01
ImCheck Therapeutics recently announced the first patient in the US has been dosed at the Yale University Cancer Center in New Haven, CT, as part…
Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm
Australian clinical-stage drug development company Noxopharm Limited recently announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its…
Brickell Biotech Completes Patient Enrollment in US Phase 3 Pivotal Cardigan I Study
Brickell Biotech, Inc. recently announced completion of patient enrollment in the Phase 3 pivotal Cardigan I study and that the Cardigan II study has surpassed…
MacroGenics Adopts Genedata Profiler to Enhance Development of Immunotherapies
Genedata recently announced a long-term partnership agreement with MacroGenics, a biopharmaceutical company and an emerging leader in developing and commercializing innovative immune-oncology therapeutics…..
Agenus Submits Balstilimab Biologics License Application to the US FDA for Patients With Recurrent or Metastatic Cervical Cancer
Agenus Inc. recently announced the submission of a Biologics License Application (BLA) to the US FDA for the accelerated approval of….
ERS Genomics & NUVISAN ICB Sign CRISPR/Cas9 License Agreement
ERS Genomics Limited and NUVISAN Innovation Campus Berlin (ICB) GmbH recently announced a non-exclusive license agreement granting NUVISAN ICB access to….
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-Based COVID-19 Vaccine Candidate
The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. recently announced initiation of a rolling submission for CVnCoV, the company’s mRNA-based COVID-19 vaccine….
XOMA’s Royalty Portfolio Grows With Addition of Three Royalty Assets
XOMA Corporation recently announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. innate cell engager…
